Valuation: Guided Therapeutics Inc

Market Cap 23.94M 21.06M 19.91M 18.06M 33.92M 2.3B 34.11M 238M 92.07M 1.17B 89.89M 87.94M 3.77B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 26.82M 23.59M 22.3M 20.23M 37.99M 2.57B 38.21M 267M 103M 1.31B 101M 98.5M 4.22B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
09-10 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
08-14 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
06-16 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
05-16 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-31 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
12-18 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
12-12 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
11-19 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
11-14 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
19/08/25 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
15/08/25 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%+3.01%+46.17%+34.91% 250B
+1.27%+5.32%+22.99%-8.03% 158B
+2.37%+3.27%-5.97%+40.06% 143B
+0.43%+0.89%-55.07%-17.35% 63.65B
+0.63%-1.71%+13.88%+24.11% 49.74B
+1.40%+8.19%+42.00%+56.44% 48.71B
+2.33%+2.38%-14.54%-18.18% 47.94B
+2.17%+4.49%+51.84%+60.86% 42.59B
+0.70%+13.85%+196.54%+105.44% 40.77B
Average +1.14%+4.02%+33.09%+30.92% 93.77B
Weighted average by Cap. +0.94%+3.84%+27.32%+26.12%

Financials

2024 2025
Net sales 7K 6.16K 5.82K 5.28K 9.92K 672K 9.97K 69.7K 26.92K 343K 26.28K 25.71K 1.1M 767K 675K 638K 579K 1.09M 73.63M 1.09M 7.64M 2.95M 37.57M 2.88M 2.82M 121M
Net income -2.42M -2.13M -2.01M -1.82M -3.42M -232M -3.44M -24.07M -9.3M -118M -9.07M -8.88M -380M -3.2M -2.81M -2.66M -2.41M -4.53M -307M -4.55M -31.83M -12.29M -157M -12M -11.74M -503M
Net Debt 1.77M 1.56M 1.47M 1.34M 2.51M 170M 2.52M 17.64M 6.81M 86.75M 6.65M 6.51M 279M 2.88M 2.53M 2.39M 2.17M 4.07M 276M 4.1M 28.64M 11.06M 141M 10.8M 10.56M 453M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-